Thanks @thevinnys - I love the back of the envelope...

Thanks @thevinnys - I love the back of the envelope calculation.
It will be very interesting to discover, as these therapies mature, how the various markets approach administering and subsidizing.
Even if the market potential in Australia is limited to $10-20M per annum in revenues, that's still a significant revenue stream to start building towards - but as you mention, like all Incannex's drug development programs, psi-GAD aims to capture the US market which is 15 times bigger. And of course the rest of the world in due course.

One thing is for certain: sadly GAD isn't going to go away on its own. The world is only getting more and more conducive to anxiety. We might find CAGR of this affliction may end up significantly higher than currently forecast by the time the decade is nearing completion.